-
Mashup Score: 0Nationwide Children's Reports High Diagnostic Yield of Combined DNA, RNA Analysis in Pediatric Cancers - 5 year(s) ago
Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.
Source: Precision Oncology NewsCategories: Latest Headlines, PediatricsTweet
-
Mashup Score: 2
Some oncologists said 10 mutations/Mb is an acceptable TMB cutoff in patients who are out of options, while others worry it will drive immunotherapy use in those unlikely to have a lasting benefit.
Source: Precision Oncology NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
Well articulated debate: Merck's Second Tissue-Agnostic Approval for Keytruda Reignites TMB Cutoff Debate | Precision Oncology News: Turna Ray https://t.co/00g8tDgEnY
-
-
Mashup Score: 0Polygenic Risk Score, Family History Refine Breast Cancer Risk Assessment in CHEK2 Mutation Carriers - 5 year(s) ago
Breast cancer risk in carriers of pathogenic CHEK2 variants may be classified as low, moderate, or high by adding in polygenic risk score and family history data.
Source: Precision Oncology NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Polygenic Risk Score, Family History Refine #BreastCancer Risk Assessment in CHEK2 Mutation Carriers #ASCO20 https://t.co/JQ1FYAd9Hv
-
-
Mashup Score: 0BRCA1/2-Positive Breast Cancer Patients May Respond to Certain Chemotherapy Regimens, Study Finds - 5 year(s) ago
Breast cancer patients with certain germline risk variants were more responsive to the chemotherapy combinations tested in a randomized trial.
Source: Precision Oncology NewsCategories: Hem/OncsTweet-
BRCA1/2-Positive Breast Cancer Patients May Respond to Certain Chemotherapy Regimens, Study Finds https://t.co/NQPNPuOvng
-
-
Mashup Score: 2GSK's sNDA for Ovarian Cancer Drug Zejula Accepted by FDA - 5 year(s) ago
The intended use will be in newly diagnosed ovarian cancer patients who are responsive to platinum chemotherapy regardless of biomarker status.
Source: Precision Oncology NewsCategories: Hem/OncsTweet-
Just out📣 @US_FDA 🇺🇸has accepted supplemental new drug💊application for niraparib as a 1️⃣st line maintenance treatment for #chemotherapy 🧪responsive advanced #OvarianCancer https://t.co/9WEV58WDfa https://t.co/9A6QAX9bar
-
-
Mashup Score: 2
Benefit was seen for patients with high TMB on Keytruda, with ERBB2 amplifications on Perjeta and Herceptin, and with BRAF mutations on Cotellic plus Zelboraf.
Source: Precision Oncology NewsCategories: Healthcare ProfessionalsTweet-
Colorectal Cancer Patients Benefit from Biomarker-Guided Treatments in TAPUR Study BRAF HER2 and MSI key to testing https://t.co/p7WxKt2uQU
-
-
Mashup Score: 0
The results arose from a PhaseIb/II trial investigating new drug candidate leronlimab for the treatment of metastatic triple-negative breast cancer.
Source: Precision Oncology NewsCategories: Healthcare ProfessionalsTweet-
CytoDyn Sees Promising Early Responses in Two Breast Cancer Patients to Leronlimab https://t.co/k1v7jPT8NB
-
Nationwide Children's Reports High Diagnostic Yield of Combined DNA, RNA Analysis in Pediatric Cancers https://t.co/bVE0v49c5U